Exelixis Announces Q3 2024 Financial Results and Update
29 Oct 2024 //
BUSINESSWIRE
Exelixis and Arcus Announce Trial Collaboration to Evaluate Zanzalintinib
04 Dec 2023 //
BUSINESSWIRE
Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial
04 Dec 2023 //
BUSINESSWIRE
Exelixis Announces Results from Expansion Cohort of Phase 1b STELLAR-001 Trial
10 Nov 2023 //
BUSINESSWIRE